Assembly Biosciences (NASDAQ:ASMB) Upgraded by UBS Group to “Strong-Buy” Rating

UBS Group upgraded shares of Assembly Biosciences (NASDAQ:ASMB) to a strong-buy rating in a research report released on Tuesday morning,Zacks reports.

Other equities analysts have also recently issued reports about the company. Wall Street Zen cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Mizuho set a $53.00 price target on shares of Assembly Biosciences in a report on Tuesday. Guggenheim reaffirmed a “buy” rating and set a $43.00 price objective on shares of Assembly Biosciences in a research report on Thursday, May 28th. Zacks Research raised shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $45.60.

Assembly Biosciences Stock Performance

Shares of NASDAQ:ASMB opened at $35.18 on Tuesday. The company has a market cap of $716.26 million, a P/E ratio of 34.49 and a beta of 1.12. Assembly Biosciences has a one year low of $20.23 and a one year high of $39.71. The business’s 50-day simple moving average is $28.55 and its 200 day simple moving average is $28.00.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.52. The company had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. Analysts predict that Assembly Biosciences will post 2.28 earnings per share for the current year.

Institutional Trading of Assembly Biosciences

Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its position in shares of Assembly Biosciences by 6,382.7% in the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 3,319 shares in the last quarter. California State Teachers Retirement System purchased a new stake in shares of Assembly Biosciences in the 2nd quarter valued at approximately $103,000. Seven Fleet Capital Management LP purchased a new stake in shares of Assembly Biosciences in the 4th quarter valued at approximately $147,000. Charles Schwab Investment Management Inc. acquired a new position in Assembly Biosciences in the 4th quarter worth approximately $228,000. Finally, Virtus Investment Advisers LLC acquired a new position in Assembly Biosciences in the 4th quarter worth approximately $251,000. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.